# Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer

> **NCT00738777** · PHASE2 · SUSPENDED · sponsor: **The Netherlands Cancer Institute** · enrollment: 250 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Anastrozole
- **DRUG:** Anastrozole+Fulvestrant
- **DRUG:** Tamoxifen
- **DRUG:** Tamoxifen

## Key facts

- **NCT ID:** NCT00738777
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2008-07
- **Primary completion:** 2022-06
- **Final completion:** 2024-06
- **Target enrollment:** 250 (ESTIMATED)
- **Why stopped:** in preparation for an amendment
- **Last updated:** 2021-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00738777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00738777, "Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00738777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*